p53 gene mutations are associated with rapid progression and poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.: A gela study.

被引：0
|
作者：
Leroy, K [1 ]
Haioun, C [1 ]
Lapage, E [1 ]
Le Métayer, N [1 ]
Berger, F [1 ]
Labouyrie, E [1 ]
Duval, C [1 ]
Meignin, V [1 ]
Petit, B [1 ]
Bastard, C [1 ]
Salles, G [1 ]
Gisselbrecht, C [1 ]
Reyes, F [1 ]
Gaulard, P [1 ]
机构：
[1] Hop Henri Mondor AP HP, Dept Pathol & EA2348, F-94010 Creteil, France
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3090
引用
收藏
页码：699A / 699A
页数：1
相关论文
共 43 条
  • [31] Long-term results of the GELA study comparing R-CHOP and CHOP chemotherapy in older patients with diffuse large B-cell lymphoma show good survival in poor-risk patients
    Coiffier, B.
    Feugier, P.
    Mounier, N.
    Franchi-Rezgui, P.
    Van den Neste, E.
    Macro, M.
    Haioun, C.
    Sebban, C.
    Bordessoule, D.
    Tilly, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [32] Expression of MYC, IgM, As Well As Non-Germinal Centre B-Cell Like Immunophenotype and Positive Immunofish Index Predict a Worse Progression Free Survival and Overall Survival in a Series of 670 De Novo Diffuse Large B-Cell Lymphomas Included in Clinical Trials: A GELA Study of the 2003 Program
    Molina, Thierry Jo
    Briere, Josette
    Copie-Bergman, Christiane
    Petrella, Tony
    Canioni, Danielle
    Delarue, Richard
    Cuilliere-Dartigues, Peggy
    Belhadj, Karim
    Fabiani, Bettina
    Peyrade, Frederic
    Parrens, Marie
    Fitoussi, Olivier
    Ketterer, Nicolas
    Recher, Christian
    Baia, Maryse
    Emile, Jean-Francois
    Ruminy, Philippe
    Haioun, Corinne
    Leroy, Karen
    Salles, Gilles
    Jais, Jean-Philippe
    Tilly, Herve
    Jardin, Fabrice
    Gaulard, Philippe
    BLOOD, 2012, 120 (21)
  • [33] Rituximab vs observation after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.: Final analysis of the LNH98-B3 GELA study.
    Haioun, C
    Mounier, N
    Emile, JF
    Feugier, P
    Coiffier, B
    Tilly, H
    Recher, C
    Fermé, C
    Gabarre, J
    Herbrecht, R
    Morschhauser, F
    Gisselbrecht, C
    BLOOD, 2005, 106 (11) : 200A - 200A
  • [34] p53 Expression Is a Strong Marker of Inferior Survival in De Novo Diffuse Large B-Cell Lymphoma and May Have Enhanced Negative Effect With MYC Coexpression A Single Institutional Clinicopathologic Study
    Xie, Yi
    Bulbul, Mohmad Ajaz
    Ji, Lingyun
    Inouye, Casey M.
    Groshen, Susan G.
    Tulpule, Anil
    O'Malley, Dennis P.
    Wang, Endi
    Siddiqi, Imran N.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (04) : 593 - 604
  • [35] Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study
    Gisselbrecht, Christian
    Fitoussi, Olivier
    Belhadj, Karim
    Mounier, Nicolas
    Feugier, Pierre
    Coiffier, Bertrand
    Recher, Christian
    Casasnovas, Olivier
    Sebban, Catherine
    Ferme, Christophe
    Briere, Josette
    Tilly, Herve
    Haioun, Corinne
    BLOOD, 2008, 112 (11) : 286 - 286
  • [36] Gene Expression Profile Analysis According to Recurrent Gene Copy Number Abnormalities Defines a Diffuse Large B-Cell Lymphoma Subgroup Characterized by 9p21 Locus Deletion, Ribosome Machinery Deregulation and Poor Prognosis. A GELA Study
    Jardin, Fabrice
    Jais, Jean-Philippe
    Molina, Thierry Jo
    Parmentier, Francoise
    Picquenot, Jean-Michel
    Ruminy, Philippe
    Tilly, Herve
    Bastard, Christian
    Salles, Gilles Andre
    Coiffier, Bertrand
    Haioun, Corinne
    Leroy, Karen
    BLOOD, 2008, 112 (11) : 298 - 299
  • [37] UNDERWEIGHT AND LOW BODY SURFACE AREAS FOR CHEMOTHERAPY DOSING ARE ASSOCIATED WITH INFERIOR SURVIVAL IN MALE PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A STUDY OF 658 R-CHOP TREATED PATIENTS
    Munksgaard, P. Svenssen
    Severinsen, M. Tang
    Bekric, E.
    Mortensen, C. Brieghel
    Jensen, K. Buchardi
    Bogsted, M.
    Bendtsen, M. Dahl
    El-Galaly, T. Christoffer
    HAEMATOLOGICA, 2015, 100 : 404 - 405
  • [38] Rituximab vs. nothing after high-dose consolidative first-line chemotherapy (HDC) with autologous stem cell transplantation in poor risk diffuse large B-cell lymphoma.: Results of the first interim analysis of the randomized LNH98-B3 GELA study.
    Haioun, C
    Mounier, N
    Emile, JF
    Feugier, P
    Coiffier, B
    Tilly, H
    Recher, C
    Fermé, C
    Gabarre, J
    Herbrecht, R
    Morschhauser, F
    Gisselbrecht, C
    BLOOD, 2003, 102 (11) : 399A - 399A
  • [39] MDM2 gene SNP309 T/G and p53 gene SNP72 G/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians
    Bittenbring, Joerg
    Parisot, Frederique
    Wabo, Alain
    Mueller, Monika
    Kerschenmeyer, Lynn
    Kreuz, Markus
    Truemper, Lorenz
    Landt, Olfert
    Menzel, Alain
    Pfreundschuh, Michael
    Roemer, Klaus
    BMC CANCER, 2008, 8 (1)
  • [40] Rituximab combined to ACVBP (R-ACVBP) as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first-line.: Preliminary results on 119 patients of a GELA phase II study.
    Belhadi, Karim
    Fitoussi, Olivier
    Haioun, Corinne
    Mounier, Nicolas
    Lederlin, Pierre
    Coiffier, Bertrand
    Recher, Christian
    Casasnovas, Olivier
    Sebban, Catherine
    Ferme, Christophe
    Tilly, Herve
    Gisselbrecht, Christian
    BLOOD, 2006, 108 (11) : 868A - 868A
12345